Selecting dopamine depleters for hyperkinetic movement disorders: how do we choose?

Laszlo Szpisjak, Andras Salamon, Denes Zadori, Peter Klivenyi, Laszlo Vecsei

Research output: Contribution to journalEditorial

Original languageEnglish
Pages (from-to)1-4
Number of pages4
JournalExpert Opinion on Pharmacotherapy
Issue number1
Publication statusPublished - Jan 2 2020


  • Deutetrabenazine
  • VMAT2 inhibitor
  • hyperkinetic
  • movement disorders
  • tetrabenazine
  • valbenazine

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this